Teriparitide update

Rheumatic Disease Clinics of North America

Volumn 37, Issue 3, 2011, Pages 471-477

  Silverman, Stuart L ^a,b,c   Nasser, Keaton ^b  

^a Cedars Sinai Bone Center of Excellence   (United States)

^b OMC Clinical Research Center   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Osteonecrosis; Osteoporosis; Postmenopausal women; Teriparitide

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; DENOSUMAB; ESTROGEN; ETIDRONIC ACID; GLUCOCORTICOID; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; PLACEBO; RALOXIFENE; RISEDRONIC ACID; ZOLEDRONIC ACID;

BACKACHE; COMBINATION CHEMOTHERAPY; CORTICOSTEROID INDUCED OSTEOPOROSIS; DOSAGE SCHEDULE COMPARISON; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; FEMUR SUBTROCHANTERIC FRACTURE; FOLLOW UP; FRACTURE; FRACTURE HEALING; HUMAN; JAW OSTEONECROSIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NONHUMAN; OSSIFICATION; OSTEOPOROSIS; PATIENT COMPLIANCE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; TOOTH IMPLANTATION; VERTEBRA FRACTURE;

BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMIDAZOLES; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; RISK FACTORS; TERIPARATIDE;

EID: 82455219376     PISSN: 0889857X     EISSN: 15583163     Source Type: Journal    
DOI: 10.1016/j.rdc.2011.08.002     Document Type: Review

References (38)

1. Neer R.M., Arnauld C.D., Zanchetta J.R., et al. Effect of PTH 1,34 on fracture and BMD in postmenopausal women with osteoporosis. N Engl J Med 2001, 344:1434-1441.
2. Black D.M., Greenspan S.L., Ensrud K.E., et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 2003, 349:1207-1215.
3. Cosman F., Eriksen E.F., Recknor C., et al. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis. J Bone Miner Res 2011, 26:503-511.
4. Ettinger B., San Martin J., Crans G., et al. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res 2004, 19:745-751.
5. Boonen S., Marin F., Obermayer-Pietsch B., et al. Effects of previous antiresorptive therapy on BMD response to two years teriparatide therapy in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2008, 93:852-860.
6. Black D.M., Bilezikian J.P., Ensrud K.E. One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. N Engl J Med 2005, 353:555-565.
7. Rittmaster R.S., Bolognese M., Ettinger M.P., et al. Enhancement of bone mass in osteoporotic women with PTH followed by alendronate. J Clin Endocrinol Metab 2000, 85:2129-2134.
8. Leder B.Z., Neer R.M., Wyland J.J., et al. Effects of teriparatide treatment and discontinuation in postmenopausal women and eugonadal men with osteoporosis. J Clin Endocrinol Metab 2009, 94:2915-2921.
9. Finkelstein J.S., Wyland J.J., Leder B.Z., et al. Effects of teriparatide retreatment in osteoporotic men and women. J Clin Endocrinol Metab 2009, 94:2495-2501.
10. Gatti D., Viapiana O., Idolazzi L., et al. The waning of teriparatide effect on bone formation markers in postmenopausal osteoporosis is associated with increasing serum levels of DKK1. J Clin Endocrinol Metab 2011, 96:1555-1559.
11. Cosman F., Nieves J., Zion M., et al. Daily and cyclic parathyroid hormone in women receiving alendronate. N Engl J Med 2005, 353:566-575.
12. Bukata S.V., Puzas J.E. Orthopedic uses of teriparatide. Curr Osteoporos Rep 2010, 8:28-33.
13. Andreassen T.T., Ejersted C., Oxlund H. Intermittent parathyroid hormone (1-34) treatment increases callus formation and mechanical strength of healing rat fractures. J Bone Miner Res 1999, 14:960-968.
14. Andreassen T.T., Willick G.E., Morley P., et al. Treatment with parathyroid hormone hPTH(1-34), hPTH(1-31), and monocyclic hPTH(1-31) enhances fracture strength and callus amount after withdrawal fracture strength and callus mechanical quality continue to increase. Calcif Tissue Int 2004, 74:351-356.
15. Alkhiary Y.M., Gerstenfeld L.C., Krall E., et al. Enhancement of experimental fracture healing by systemic administration of recombinant human parathyroid hormone (PTH 1-34). J Bone Joint Surg Am 2005, 87:731-741.
16. Friedl G., Turner R.T., Evans G.L., et al. Intermittent parathyroid hormone (PTH) treatment and age-dependent effects on rat cancellous bone and mineral metabolism. J Orthop Res 2007, 25:1454-1464.
17. Nakazawa T., Nakajima A., Shiomi K., et al. Effects of low-dose, intermittent treatment with recombinant human parathyroid hormone (1-34) on chondrogenesis in a model of experimental fracture healing. Bone 2005, 37:711-719.
18. Kakar S., Einhorn T.A., Vora S., et al. Enhanced chondrogenesis and Wnt signaling in PTH-treated fractures. J Bone Miner Res 2007, 22:1903-1912.
19. O'Loughlin P.F., Cunningham M.E., Bukata S.V., et al. Parathyroid hormone (1-34) augments spinal fusion, fusion mass volume, and fusion mass quality in a rabbit spinal fusion model. Spine (Phila Pa 1976) 2009, 34:121-130.
20. Manabe T., Mori S., Mashiba T., et al. Human parathyroid hormone (1-34) accelerates natural fracture healing process in the femoral osteotomy model of cynomolgus monkeys. Bone 2007, 40:1475-1482.
21. Resmini G., Iolascon G. 79-year-old postmenopausal woman with humerus fracture during teriparatide treatment. Aging Clin Exp Res 2007, 19:30-31.
22. Peichl P., Krankenhaus Wien Waehring E., Holzer G. Parathyroid hormone (1-84) accelerates fracture healing in pubic bones of elderly osteoporotic women. J Bone Miner Res 2009, 24(Suppl 1). Available at:, Accessed August 20, 2011. http://www.asbmr.org/Meetings/AnnualMeetings/AbstractDetail.aspx?aid=9d4e83f0-6302-4327-8a9d-758dc56cc703.
23. Bukata SV, Kaback L, Reynolds D, et al. 1-34 PTH at physiological doses in humans shows promise as a helpful adjuvant in difficult to heal fractures: an observational cohort of 145 patients. Presented at the 55th Annual Meeting of the Orthopaedic Research Society. Las Vegas (Nevada), February 25, 2009.
24. Aspenberg P., Genant H.K., Johansson T. Teriparatide for accelaration of fracture repair in humans: a prospective randomized double blind study of 102 postmenopausal women with distal radial fractures. J Bone Miner Res 2010, 25:404-414.
25. Aspenberg P., Johansson T. Teriparatide improves early callus formation in distal radial fractures. Acta Orthop 2010, 81:234-236.
26. Gomberg S.J., Wustrack R.L., Napoli N., et al. Teriparatide, vitamin D and calcium-healed bilateral subtrochanteric stress fractures in a postmenopausal woman with a 13-year history of continuous alendronate therapy. J Clin Endocrinol Metab 2011, 96:1627-1632.
27. Carvalho N.N., Voss L.A., Almeida M.O., et al. Atypical fremoral fractures during prolonged use of bisphosphonates: short term responses to strontium ranelate and teriparatide. J Clin Endocrinol Metab 2011, [Epub ahead of print].
28. Narongroeknawin P., Danila M., Humphreys L.G., et al. Bisphosphonate associated 27. osteonecrosis of the jaw, with healing after teriparatide: a review of the literature and a case report. Spec Care Dentist 2010, 30:77-82.
29. Kuchler U., Luvizuto E.R., Tangl S., et al. Short term teriparatide delivery and osseointegration: a clinical feasibility study. J Dent Res 2011, 90:1001-1006.
30. Bashutski J.D., Eber R.M., Kinney J.S., et al. Teriparatide and osseous regeneration in the oral cavity. N Engl J Med 2010, 363:2396-2405.
31. Cejka D., Kodras K., Bader T., et al. Treatment of hemodialysis associated adynamic bone disease with teriparatide: a pilot study. Kidney Blood Press Res 2010, 33:221-226.
32. Fabbriciani G., Pirro M., Manfredelli M., et al. Transient osteoporosis of the hip: successful treatment with teriparatide. Rheumatol Int 2010, [Epub ahead of print].
33. Lyritis G., Marin F., Barker C., et al. Back pain during different sequential treatment regimens of teriparitide: results from Eurofors. Curr Med Res Opin 2010, 26:1799-1807.
34. Petal H. Effect of teriparatide compared with risedonate on back pain and incident vertebral fractures in postmenopausal women with ostropeodic vertebral fractures Presented at European Calcified Tissue Society. May 7-11, Athenes, Greece, 2011.
35. Canalis E., Bilezikian J.P., Angeli A., et al. Perspectives on glucocorticoid induced osteoporosis. Bone 2004, 34:593-598.
36. Love N.E., Sanchez S., Modin G.W. Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis: results of a randomized controlled clinical trial. J Clin Invest 1998, 102:1627-1633.
37. Saag K.G., Zanchetta J.R., Devogelaer J.P., et al. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six months results of a randomized, double-blind, controlled trial. Arthritis Rheum 2009, 60:3346-3355.
38. Foster S.A., Foley K.A., Meadows E.S., et al. Adherence and persistence with teriparatide among patients with commercial, Medicare, and Medicaid insurance. Osteoporos Int 2011, 22:551-557.